Foghorn Therapeutics

Foghorn Therapeutics doses first patient in AML therapy trial
Clinical Trials Arena
Fri, 09/1/23 - 11:57 am
Foghorn Therapeutics
FHD-286
AML
Foghorn Abandons Uveal Melanoma Program after Subpar Phase I Results
BioSpace
Thu, 06/29/23 - 11:48 am
Foghorn Therapeutics
uveal melanoma
AML
FHD-286
Foghorn sinks plans for eye tumor drug after glimpsing phase 1 data
Fierce Biotech
Wed, 06/28/23 - 10:30 am
Foghorn Therapeutics
FHD-286
eye cancer
clinical trials
Foghorn finally has clear route back to clinic after FDA lifts yearlong hold on blood cancer drug
Fierce Biotech
Tue, 06/6/23 - 10:01 am
Foghorn Therapeutics
FHD-286
FDA
blood cancer
FDA Presses Pause on Another Foghorn Program
BioSpace
Tue, 04/25/23 - 10:31 am
Foghorn Therapeutics
FDA
FHD-609
QTc
Foghorn sounds another warning about the class of ‘20
EP Vantage
Thu, 08/25/22 - 10:52 am
Foghorn Therapeutics
IPOs
COVID-19
pandemic
biotech
Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS
BioSpace
Tue, 08/23/22 - 10:35 am
Foghorn Therapeutics
FHD-286
AML
MDS
FDA
clinical trials
FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial
Benzinga
Fri, 05/20/22 - 10:28 am
Foghorn Therapeutics
clinical trials
FDA
FHD-286
acute myelogenous leukemia
AML
patient death
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform
PR Newswire
Mon, 12/13/21 - 10:51 am
Eli Lilly
Foghorn Therapeutics
oncology
Foghorn hits Nasdaq in $120M debut as the biotech IPO boom shows no sign of slowing
Endpoints
Fri, 10/23/20 - 11:57 am
Foghorn Therapeutics
IPOs
NASDAQ
chromatin regulatory system
Foghorn blows its klaxon, gunning for a $100M IPO hot on the heels of its Merck deal
Fierce Biotech
Mon, 10/5/20 - 10:58 am
Foghorn Therapeutics
IPOs
Merck
chromatin regulatory system
Merck teams up with cancer startup Foghorn in $425M deal
Fierce Biotech
Wed, 07/8/20 - 10:48 am
Merck
Foghorn Therapeutics
cancer
drug development